News

Flagship Biosciences to Present at the Next Generation Dx Summit

Back to News

Get the Whole Picture with both Content and Context

August 9, 2017 – Westminster, CO – Flagship Biosciences, the leading partner for drug developers investigating tissue-based biomarkers, announced today that they will be a significant contributor to the strategic and scientific dialogue at the Next Generation Dx Summit in Washington DC, August 14th – 16th. Flagship’s Chief Scientific Officer, Dr. Joseph Krueger will be chairing a session and Scientist, Dr. Allison Harney, will be presenting data at the Next Generation Dx Summit:

  • August 15th, 2017 – Program: Companion Diagnostics: Strategy & Partnerships
    • 10:55 am Session: Novel Technologies, Approaches, IO Hype.
      Chairperson’s Opening Remarks: Dr. Joseph Krueger, PhD, CSO Flagship Biosciences
  • Poster Presentations by Scientist Dr. Allison Harney:
    • Evaluating Image Analysis Approaches Toward “Harmonization” of PD-L1 Assays
      • Tues. – Aug. 15th
        10:10am – 10:55am
        1:30am – 2:00pm
        4:05pm – 4:50pm
        5:50pm – 6:50pm
      • Wed. – Aug. 16th
        10:30am – 11:15am
    • Multiparametric Immunohistochemistry Quantification with Computational Tissue Analysis
      • Wed. – Aug. 16th
        1:35pm – 2:05pm
        4:10pm – 5:00pm
      • Thurs. – Aug. 17th
        10:00am – 11:00am
  • For a quick reference to Flagship’s activities at the summit, download the Quickguide.

    Flagship’s Computational Tissue Analysis (cTA™) and Data-Driven-Decision Support Platform has been created to precisely quantify many features of an IHC biomarker assay that can be challenging or even impossible to visually quantify. Combining the contextual tissue data from cTA™ with the content from other diagnostic modalities can give drug developers deeper insights into the biology and complexities of the tumor microenvironment, and lead to more confident clinical pipeline decision making.

    As the largest tissue image analysis operation in the world, Flagship has worked with over 100 pharma and biotech companies to provide the quantitative and contextual tissue interpretation to make timely decisions.

    Connect with Flagship at the Next Generation Dx Summit at their presentations or booth #415 to learn how data-rich, tissue context information can be combined with genomic data to support I/O drug development and provide clarity to diagnostic decisions.

    Find out more:

    White Paper: The Future of Diagnostics for Immuno-Oncology

    Blog: Combining Genomic Profiling and Tissue-Based Biomarker Assays to Aid in the Early Detection and Prevention of Cancer

    Follow Flagship on Twitter @FlagshipBio

    Share this Post: